TMCnet News

Shattuck Labs Announces Participation in Upcoming May Conferences
[April 30, 2021]

Shattuck Labs Announces Participation in Upcoming May Conferences


AUSTIN, TX and DURHAM, NC, April 30, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer, will participate in two upcoming conferences.

Presentation Details
Conference: 32nd Annual Cello Health Cancer Progress Conference
Title: Multifunctional Soluble Biologics: Binders, Binders Everywhere
Format: Panel discussion
Date: May 5, 2021
Time: 11:45 a.m. EST

Conference: 17th Annual PEGS Boston Conference
Title: Ranking Product Attributes to Select an Appropriate Expression Platform
Format: Panel discussion
Date: May 11, 2021
Time: 12:20 p.m. EST

The presentations and panel discussions will be available to registered conference attendees.

About Shattuck Las, Inc.



Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company’s lead wholly owned program, SL-172154 (SIRPa-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

Investor Contact:
Conor Richardson
Senior Director, Finance & Investor Relations
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com


Media Contact:
Stephanie Ascher
Managing Director
Stern Investor Relations, Inc.
Stephanie.ascher@sternir.com 


Primary Logo


[ Back To TMCnet.com's Homepage ]